| 104.20 Delayed Data As of May 24 |  +0.43 / +0.41%Today’s Change | 89.01 Today|||52-Week Range 122.97 | +8.06% Year-to-Date |
The investment seeks to track the investment results of the NASDAQ Biotechnology Index, which contains securities of companies listed on NASDAQ that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by Nasdaq, Inc. The fund generally invests at least 90% of its assets in securities of the index and in depositary receipts representing securities of the index. It may invest the remainder of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
| Advisory Services Network, LLC Buys iShares Core U.S. ... May 20 / GuruFocus NewsGURU - Paid Partner Content |
| 1 month | -1.27% | 3 years | +4.97% | |
| 3 months | -5.91% | 5 years | +6.10% | |
| 1 year | -2.70% | Since inception | +6.59% |
| Previous close | $103.77 |
| Open day’s range | 103.83 – 105.17 |
| Net asset value (NAV) | 104.24 (05/24/2019) |
| Daily volume | 1,342,149 |
| Average volume (3 months) | 2,486,501 |
| IBB | Category | |
|---|---|---|
| Performance 5-yr return | +6.10% | +10.02% |
| Expense Gross exp ratio | 0.47% | 1.26% |
| Risk 5 year sharpe ratio | 0.37 | 0.60 |
| Net assets | $7.7B | $3.0B |
| Average market cap | $13.8B | $34.4B |
| Average P/E | 17.3 | 24.9 |
| Dividend / Share | -- | 0.26% |
| FHLC Fidelity® MSCI Health Care Index ETF |
| VHT Vanguard Health Care Index Fund ETF Shar... |
| IHI iShares U.S. Medical Devices ETF |
| Healthcare | 99.91% |
| Business service | 0.09% |
| Consumer goods | 0.00% |
| Consumer service | 0.00% |
| Energy | 0.00% |
| CELG Celgene | 8.54% |
| GILD Gilead Sciences | 8.46% |
| AMGN Amgen | 7.98% |
| BIIB Biogen | 5.79% |
| VRTX Vertex Pharmaceuticals Inc | 5.55% |
| ILMN Illumina Inc | 4.22% |
| ALXN Alexion Pharmaceuticals Inc | 4.15% |
| REGN Regeneron Pharmaceuticals | 3.37% |
| INCY Incyte Corp | 2.24% |
| BMRN Biomarin Pharmaceutical Inc | 2.08% |
